leponex 25 mg tabletten
viatris healthcare gmbh (8009064) - clozapin - tablette - teil 1 - tablette; clozapin (09458) 25 milligramm
leponex 100 mg tabletten
viatris healthcare gmbh (8009064) - clozapin - tablette - teil 1 - tablette; clozapin (09458) 100 milligramm
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotische mittel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
certoparin viatris 3.000 ie injektionslösung in fertigspritze
viatris healthcare gmbh (8009064) - injektionslösung in einer fertigspritze - 3000 i.e.
certoparin viatris 8.000 ie injektionslösung in fertigspritze
viatris healthcare gmbh (8009064) - injektionslösung in einer fertigspritze - 8000 i.e.
atorvastatin viatris 20 mg kautabletten
viatris pharma gmbh (8183833) - atorvastatin-calcium-trihydrat (ph.eur.) - kautablette - teil 1 - kautablette; atorvastatin-calcium-trihydrat (ph.eur.) (28860) 21,7 milligramm
atorvastatin viatris 40 mg kautabletten
viatris pharma gmbh (8183833) - atorvastatin-calcium-trihydrat (ph.eur.) - kautablette - teil 1 - kautablette; atorvastatin-calcium-trihydrat (ph.eur.) (28860) 43,4 milligramm
atorvastatin viatris 10 mg kautabletten
viatris pharma gmbh (8183833) - atorvastatin-calcium-trihydrat (ph.eur.) - kautablette - teil 1 - kautablette; atorvastatin-calcium-trihydrat (ph.eur.) (28860) 10,85 milligramm
atorvastatin viatris 5 mg kautabletten
viatris pharma gmbh (8183833) - atorvastatin-calcium-trihydrat (ph.eur.) - kautablette - teil 1 - kautablette; atorvastatin-calcium-trihydrat (ph.eur.) (28860) 5,425 milligramm
amlodipin valsartan hct viatris 5 mg/160 mg/12.5 mg filmtabletten
viatris pharma gmbh - amlodipinum, valsartanum, hydrochlorothiazidum - filmtabletten - filmtablette: amlodipinum 5 mg ut amlodipini besilas 6.944 mg, valsartanum 160 mg, hydrochlorothiazidum 12.5 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 4000, talcum, e 171, pro compresso obducto. - essentielle hypertonie - synthetika